We are going through some challenges as Coronavirus spreads all over the world.It makes sense for us to be braced and have knowledge on best approaches to help our body fight the virus, in case it will be needed. We put together several informations and research content about supplements that can help fighting virus infections for you.

Mechanical ventilator can mean life or death for patients with severe symptoms. Unfortunatly, they’re in short supply all over the globe.

Now, research suggests that a common used clot-busting stroke drug could help COVID-19 patients who don’t have access to a ventilator or who are still struggling to improve even when they get access to a ventilation machine.

The research put eye on a drug called tissue plasminogen activator (tPA), normally it is used to break down blood clots that cause strokes or heart attacks.

Data from China and Italy tell that people with COVID-19 have struggles with blood-clotting disorders. Patients in respiratory failure can develop blood clots in the lungs and tiny blockages in the lung’s blood vessels. Blood is stopped from reaching the air spaces in the lungs by these clots, usually the blood gets it’s oxygen exactly from these spots.

“This is a way to repurpose a drug for which there is already widespread clinical utility,” said senior researcher Dr. Michael Yaffe, (professor of biology and biological engineering at MIT.

“Everyone is looking for ways to mitigate the threat of this disease, and there’s a lot of investment and interest in new drugs,” Moore said. “But if this disease gets out of control, those drugs won’t have had safety evaluations. TPA has.”
– Dr. Hunter Moore (study co-author)

While the use of the drug is well-studied in stroke and heart attack, the use of tPA in connection to acute respiratory distress syndrome has mostly been watched on animals. But there has been a small human trial which was conducted in 2001 on people with severe respiratory distress who low surviving expectations.

The death rate in those patients was reduced by 100% to 70%.

Ongoing studies haven’t been done yet because patients regulary health statuses improve quite well with the support of ventilators, the researchers added.
But as Coronavirus is stretching out the capabilities of the health care system, there is a shortage of ventilators for patients who need them.

“TPA may potentially hold therapeutic value in treating severely ill COVID-19 patients with acute respiratory distress syndrome that is unresponsive to typical ventilation strategies,” said Dr. Robert Glatter, an emergency physician at Lenox Hill Hospital in New York City.

Researchers are planning a “compassionate use” trial of the drug on COVID-19 patients, possibly beginning within a week, to see if tPA helps these patients. They will be assessing both intravenous tPA and inhaled tPA.